Latest Oncolytic virus Stories
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif., Dec.
CALGARY, Dec. 4, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
CALGARY, Dec. 2, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S.
CALGARY, Nov. 18, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS The global cancer immunotherapies market reached $30.8 billion in 2012.
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.
SAN DIEGO, Oct. 7, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S.
In the news release, Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S.
CALGARY, Sept. 3, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
- A transitional zone between two communities containing the characteristic species of each.